The ARRB2 Knockout SK-HEP-1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population targeting the ARRB2 gene in the SK-HEP-1 human liver adenocarcinoma cell line. This product provides a heterogeneous pool of gene-disrupted cells, enabling the study of ARRB2 loss-of-function effects in a hepatic cancer context. Generated using CRISPR/Cas9-mediated gene disruption, the polyclonal format offers a robust model for functional genomics without the bias of individual clones.
SK-HEP-1 cells, originally isolated from the ascitic fluid of a patient with hepatic adenocarcinoma, display an unusual combination of epithelial morphology and endothelial-like features. This cell line is widely employed in hepatocellular carcinoma research to investigate mechanisms of tumor progression, metastatic dissemination, and therapeutic resistance, making it a valuable host for ARRB2 knockout studies.
ARRB2 encodes ??-arrestin-2, a multifunctional scaffold protein that orchestrates the desensitization and clathrin-mediated internalization of activated G protein-coupled receptors (GPCRs) in cooperation with GRKs and AP-2. Beyond terminating G protein-dependent signals, ??-arrestin-2 serves as a platform for G protein-independent signaling, assembling modules that include Src, Raf, MEK, and ERK1/2 to activate MAPK cascades, as well as JNK and p38 pathways. Through these interactions, ARRB2 integrates signals from diverse receptors to modulate gene expression via transcription factors such as AP-1 and NF-??B, influencing cell proliferation, migration, and survival.
In the SK-HEP-1 hepatic adenocarcinoma model, disruption of ARRB2 function provides a powerful tool to dissect its role in GPCR-driven oncogenic signaling. Loss of ??-arrestin-2 is predicted to impair receptor internalization and attenuate MAPK/ERK and PI3K/Akt pathway activation, potentially reducing the proliferative and migratory capacity of these tumor cells. Given the involvement of ARRB2 in pathways frequently dysregulated in hepatocellular carcinoma??including Wnt, Hedgehog, and growth factor receptor signaling??this knockout population enables systematic investigation of ??-arrestin-2-dependent mechanisms contributing to liver cancer progression.
Researchers can utilize ARRB2 Knockout SK-HEP-1 Polyclonal Cells to investigate GPCR endocytosis kinetics, assess ??-arrestin-2?Cdependent MAPK/ERK phosphorylation by western blotting, or evaluate changes in cell migration using Transwell assays. The polyclonal knockout format is particularly suited for high-throughput screens to identify biased GPCR ligands or for validating the specificity of pharmacological inhibitors targeting ARRB2 interactors. Co-immunoprecipitation and BRET-based recruitment assays may be employed to map altered protein?Cprotein interaction networks in the absence of ??-arrestin-2. For further details on this product and its application in your research, please contact Ascent Research.
